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Introduction
Neonatal diabetes, defined as onset of diabetes within the 
first 6 months of life, is a genetically heterogeneous condition 
with 22 known genetic causes (1,2,3). Its causal genes are 
involved in the development of the pancreas or islets; beta 
cell apoptosis or destruction; or beta-cell function (1). The 
PTF1A gene on chromosome 10 encodes a transcription 
factor with a key role in early pancreas development and 
cerebellar neurogenesis (4,5). Homozygous truncating 
mutations in PTF1A have been reported in patients with 
pancreatic and cerebellar agenesis, whilst mutations located 
in a distal pancreatic-specific enhancer cause isolated 
pancreatic agenesis (5,6,7,8).
Here, we report a patient with isolated pancreatic agenesis 
due to compound heterozygous mutations in PTF1A: A 
coding frameshift mutation (p.Ala146Glyfs*116) and a 
novel regulatory mutation located in the distal enhancer, 25 
kb downstream of this gene.
Neonatal diabetes, defined as the onset of diabetes within the first six months of life, is very rarely caused by pancreatic agenesis. 
Homozygous truncating mutations in the PTF1A gene, which encodes a transcriptional factor, have been reported in patients with 
pancreatic and cerebellar agenesis, whilst mutations located in a distal pancreatic-specific enhancer cause isolated pancreatic agenesis. 
We report an infant, born to healthy non-consanguineous parents, with neonatal diabetes due to pancreatic agenesis. Initial genetic 
investigation included sequencing of KCNJ11, ABCC8 and INS genes, but no mutations were found. Following this, 22 neonatal diabetes 
associated genes were analyzed by a next generation sequencing assay. We found compound heterozygous mutations in the PTF1A 
gene: A frameshift mutation in exon 1 (c.437_462 del, p.Ala146Glyfs*116) and a mutation affecting a highly conserved nucleotide within 
the distal pancreatic enhancer (g.23508442A>G). Both mutations were confirmed by Sanger sequencing. Isolated pancreatic agenesis 
resulting from compound heterozygosity for truncating and enhancer mutations in the PTF1A gene has not been previously reported. 
This report broadens the spectrum of mutations causing pancreatic agenesis.
Keywords: Pancreatic agenesis, neonatal diabetes, PTF1A gene
Abstract
What is already known on this topic?
What this study adds?
This is the first report of a patient with isolated pancreatic agenesis resulting from compound heterozygosity for truncating and enhancer 
mutations in the PTF1A gene. This study broadens the spectrum of mutations causing pancreatic agenesis and the phenotypic variability 
of this condition.
Homozygous truncating mutations in PTF1A have been reported in patients with pancreatic and cerebellar agenesis, while recessive 
mutations located in a distal PTF1A enhancer cause isolated pancreatic agenesis.
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Case Report
The index patient is a 1-year and 9-month-old boy, the second 
child of healthy, Caucasian, non-consanguineous parents. 
He was born with a birth weight of 1,935 g (below the third 
percentile), length of 43 cm (below the third percentile), and 
head circumference of 32 cm (third percentile). Intrauterine 
growth retardation was noted at 34 weeks of gestation, 
and the delivery was by cesarean section at 37 weeks of 
gestation. Physical examination revealed no dysmorphic 
features. During the first week of life, hyperglycemia (blood 
glucose=250 mg/dL) without ketoacidosis was observed, 
and treatment with subcutaneous NPH insulin was initiated 
on the 7th day of life, followed by continuous subcutaneous 
insulin infusion. Despite intensive insulin therapy, the infant 
did not show satisfactory weight gain and at 4 months of 
age, his weight was 3,670 g (still below the third percentile). 
Abdominal distension and fatty stools were noted. 
Abdominal ultrasound was performed at that time and the 
pancreas could not be identified. No other abnormality was 
found. Pancreatic enzyme replacement was begun at the 
age of 4 months and a catch-up growth occurred (Figure 1). 
Over the subsequent months, his growth was satisfactory 
and his developmental milestones were all reached at an 
appropriate age.
Genetic Analysis
Initial Sanger sequencing of the coding and flaking intronic 
regions of the KCNJ11 (NM_000525), ABCC8 (NM_000352), 
and INS (NM_000207) genes was undertaken as previously 
described (3), but no mutations were found. Following this, a 
next-generation sequencing assay was performed to analyze 
the coding regions and conserved splice sites of the 22 neonatal 
diabetes genes: KCNJ11, ABCC8, INS, EIF2AK3, FOXP3, GATA4, 
GATA6, GCK, GLIS3, HNF1B, IER3IP1, PDX1, PTF1A, NEUROD1, 
NEUROG3, NKX2-2, RFX6, SLC2A2, SLC19A2, STAT3, WFS1, 
and ZFP57 (Agilent custom capture v5.1/Illumina HiSeq) 
at the Molecular Genetics Laboratory, University of Exeter 
Medical School, UK (9). A compound heterozygous mutations 
in the PTF1A gene was found: a frameshift mutation in exon 1 
(c.437_462 del, p.Ala146Glyfs*116) and a mutation affecting 
a highly conserved nucleotide within the distal pancreatic 
enhancer (g.23508442A>G) (Figure 2). The two mutations 
were predicted to be pathogenic and likely to be pathogenic, 
respectively, according to the American College of Medical 
Genetics and Genomics variant interpretation guidelines 
(10). Both mutations were confirmed by Sanger sequencing. 
Family member testing showed that the proband’s mother 
is a heterozygous carrier of the distal enhancer mutation 
and the father is a heterozygous carrier of the frameshift 
mutation. 
Discussion
Pancreatic agenesis characterized by exocrine pancreatic 
insufficiency and permanent neonatal diabetes (11) is a rare 
condition. An international cohort study of patients with 
diabetes diagnosed before 6 months of age found that only 
4.9% of them had pancreatic agenesis (12). Mutations in 
genes that encode transcription factors with a key role in 
pancreatic development, such as PDX1, GATA6, GATA4, and 
PTF1A, have been reported as genetic causes of congenital 
absence of the pancreas (5,6,7,8,12,13,14). However, the 
origin of this disorder remains unknown in ~15% of patients 
(De Franco E, unpublished data). Here, we report a patient 
with neonatal diabetes and exocrine pancreas insufficiency 
resulting from compound heterozygous mutations in 
the PTF1A gene. PTF1A, a 48kDa binding subunit of the 
pancreatic transcription factor 1 (PTF1), is required for 
normal pancreas development (4). This transcription factor 
is also expressed in embryonic neural tissues and plays a 
role in cerebellar neurogenesis. Ptf1a-/- mice show a size 
reduction in the cerebellar primordium in embryos, resulting 
in cerebellar agenesis at birth (5). Consistently with this, 
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Figure 1. Growth of the patient plotted on the World Health 
Organization growth chart. Arrow denotes the start of 
pancreatic enzyme replacement
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recessive loss of function mutations in the PTF1A gene have 
been previously reported to cause agenesis of the pancreas 
and the cerebellum with additional dysmorphic features 
(5,6,15). A homozygous missense mutation, p.Pro191Thr, 
resulting in a protein with a 75% reduced transactivation 
activity, has been recently reported in patients with isolated 
pancreatic aplasia/hypoplasia, indicating a correlation 
between coding mutation severity and phenotype (16). 
Furthermore, mutations in the enhancer region located 
25 kb downstream from the coding region of the PTF1A 
gene, which acts as a developmental enhancer of this gene, 
have been found to cause isolated pancreatic hypoplasia/
agenesis, sparing the cerebellum (7,8).
To the best of our knowledge, this is the first report of a 
patient with isolated pancreatic agenesis resulting from 
compound heterozygosity for truncating and enhancer 
mutations in the PTF1A gene. Regarding the age of onset of 
diabetes, previous reports of patients with PTF1A truncating 
mutations showed that they had diabetes in the first month 
of life (5,6,15). However, patients with PTF1A enhancer 
mutations had phenotypic variability: The majority of 
cases are diagnosed in the first month of life, but diabetes 
at later ages was also observed (8). The patient we report 
had diabetes diagnosed in the first week of life and his 
neurological development has been normal, indicating 
no associated anomaly in the cerebellum. Interestingly, 
the lack of a severe neurological phenotype in patients 
with homozygous/compound heterozygous regulatory 
mutations has been recently reported for another congenital 
disease, polycystic kidney disease with hyperinsulinemic 
hypoglycemia (HIPKD) (17). A specific promoter mutation 
in the PMM2 gene, either homozygous or in trans with a 
coding PMM2 mutation, was reported to cause HIPKD 
in 11 families. Homozygous coding mutations in PMM2 
have been previously reported to cause a congenital 
disorder of glycosylation type 1a, a severe multisystem 
disease with prominent neurologic features which were 
not observed in patients with the promoter mutation. The 
phenotype-genotype relationship observed in patients with 
coding versus non-coding mutations in PTF1A and PMM2 
highlights the fundamental role of non-coding sequences in 
development of specific organs. 
In summary, we report the case of a patient with isolated 
pancreatic agenesis due to compound heterozygosity 
for a truncating and novel enhancer mutation in PTF1A, 
broadening the spectrum of mutations causing pancreatic 
agenesis and phenotypic variability of this condition.
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